Francesco Ursini

Pubblicazioni antecedenti il 2004

1. Ursini, F., et al., COVID-19 and diabetes: Is metformin a friend or foe? Diabetes Res Clin
Pract, 2020. 164: p. 108167.
2. Spinardi, L., et al., Acute-onset focal neurological deficits in rheumatoid arthritis: consider
rheumatoid meningitis. Rheumatology (Oxford), 2020.
3. Spampinato, M.D., et al., Assessing Pretest Clinical Risk of Pulmonary Thromboembolism in
the Emergency Department: Proposal of a Simple Modification to the Wells' Score. J Emerg Med,
2020. 58(3): p. 385-390.
4. Ruscitti, P., et al., The reduction of concomitant glucocorticoids dosage following treatment
with IL-1 receptor antagonist in adult onset Still’s disease. A systematic review and meta-analysis of
observational studies. Therapeutic Advances in Musculoskeletal Disease, 2020.
5. Pucino, V., et al., Metabolic Checkpoints in Rheumatoid Arthritis. Front Physiol, 2020. 11: p.
347.
6. Pata, F., F. Ursini, and G. Gallo, Revenge lawsuit is a puzzle piece of the global crisis of
Italian healthcare system. Int J Surg, 2020. 77: p. 94-95.
7. Pascarella, A., et al., The efficacy of perampanel as adjunctive therapy in drug-resistant focal
epilepsy in a "real world" context: focus on temporal lobe epilepsy. J Neurol Sci, 2020. 415: p. 116903.
8. Guarino, M., et al., Chronobiology of acute pancreatitis in a single Italian centre. Eur Rev
Med Pharmacol Sci, 2020. 24(4): p. 1988-1994.
9. Ferri, C., et al., COVID-19 and rheumatic autoimmune systemic diseases: report of a large
Italian patients series. Clinical Rheumatology (Accepted manuscript), 2020.
10. Ciaffi, J., et al., Google trends and COVID-19 in Italy: could we brace for impact? Intern
29/6/20 © Unione europea, 2002-2020 | http://europass.cedefop.europa.eu Pagina 7 / 11
Curriculum vitae Ursini Francesco
Emerg Med, 2020: p. 1-5.
11. Ciaffi, J., et al., Sclerochoroidal calcifications associated with early-onset calcium
pyrophosphate deposition disease. Clin Rheumatol, 2020.
12. Chiaravalloti, A., et al., [18F] FBB cortical uptake is not related to the age of onset of
Alzheimer's disease. Nucl Med Commun, 2020. 41(2): p. 175-180.
13. Ursini, F., et al., The effect of non-TNF-targeted biologics on vascular dysfunction in
rheumatoid arthritis: A systematic literature review. Autoimmun Rev, 2019. 18(5): p. 501-509.
14. Ruscitti, P., et al., IL-1 inhibition improves insulin resistance and adipokines in rheumatoid
arthritis patients with comorbid type 2 diabetes: An observational study. Medicine (Baltimore), 2019.
98(7): p. e14587.
15. Peluso, R., et al., Biomarkers of subclinical atherosclerosis in patients with psoriatic arthritis.
Open Access Rheumatol, 2019. 11: p. 143-156.
16. Lyutakov, I., et al., Methods for diagnosing bile acid malabsorption: a systematic review.
BMC Gastroenterol, 2019. 19(1): p. 185.
17. Giacomelli, R., et al., Guidelines for biomarkers in autoimmune rheumatic diseases -
evidence based analysis. Autoimmun Rev, 2019. 18(1): p. 93-106.
18. Flacco, M.E., et al., Costs of irritable bowel syndrome in European countries with universal
healthcare coverage: a meta-analysis. Eur Rev Med Pharmacol Sci, 2019. 23(7): p. 2986-3000.
19. Chiaravalloti, A., et al., Overall survival and progression-free survival in patients with primary
brain tumors after treatment: is the outcome of [(18)F] FDOPA PET a prognostic factor in these
patients? Ann Nucl Med, 2019. 33(7): p. 471-480.
20. Chiaravalloti, A., et al., Brain metabolic patterns in patients with suspected non-Alzheimer's
pathophysiology (SNAP) and Alzheimer's disease (AD): is [(18)F] FDG a specific biomarker in these
patients? Eur J Nucl Med Mol Imaging, 2019. 46(9): p. 1796-1805.
21. Caio, G., et al., Small bowel adenocarcinoma as a complication of celiac disease: clinical
and diagnostic features. BMC Gastroenterol, 2019. 19(1): p. 45.
22. Ursini, F., et al., Serum Complement C3 and Type 2 Diabetes in Rheumatoid Arthritis: A
Case-Control Study. Rev Recent Clin Trials, 2018. 13(3): p. 215-221.
23. Ursini, F., et al., The effect of non-TNF-targeted biologics and small molecules on insulin
resistance in inflammatory arthritis. Autoimmun Rev, 2018. 17(4): p. 399-404.
24. Ursini, F., et al., Metformin and Autoimmunity: A "New Deal" of an Old Drug. Front Immunol,
2018. 9: p. 1236.
25. Ursini, F., et al., Current treatment options for psoriatic arthritis: spotlight on abatacept. Ther
Clin Risk Manag, 2018. 14: p. 1053-1059.
26. Ursini, F. and P. Ruscitti, Cardiometabolic Comorbidities in Autoimmune Rheumatic
Diseases: From Pathogenesis to Treatment. Rev Recent Clin Trials, 2018. 13(3): p. 162-163.
27. Ursini, F., G. De Sarro, and A. Chiaravalloti, Coupled Imaging with [(18)F]FBB and
[(18)F]FDG in AD Subjects Show a Selective Association Between Amyloid Burden and Cortical
Dysfunction in the Brain. PLoS One, 2018. 20(4): p. 659-666.
28. Ursini, F. and L. Abenavoli, The Emerging Role of Complement C3 as A Biomarker of Insulin
Resistance and Cardiometabolic Diseases: Preclinical and Clinical Evidence. Rev Recent Clin Trials,
2018. 13(1): p. 61-68.
29. Ursini, F., Response to the letter to the editor by Shadmani et al. Eur J Clin Invest, 2018.
48(2).
30. Peluso, R., et al., Cardiovascular Risk Markers and Major Adverse Cardiovascular Events in
Psoriatic Arthritis Patients. Rev Recent Clin Trials, 2018. 13(3): p. 199-209.
31. Palleria, C., et al., Implementing a simple pharmacovigilance program to improve reporting
of adverse events associated with biologic therapy in rheumatology: Preliminary results from the
Calabria Biologics Pharmacovigilance Program (CBPP). 2018. 13(10): p. e0205134.
32. Mauro, D., et al., Role of Positron Emission Tomography for Central Nervous System
Involvement in Systemic Autoimmune Diseases: Status and Perspectives. Curr Med Chem, 2018.
25(26): p. 3096-3104.
33. Leporini, C., et al., Insulin-Sensiting Effects of Tumor Necrosis Factor Alpha Inhibitors in
Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Rev Recent Clin Trials, 2018. 13(3): p.
184-191.
34. D'Angelo, S., et al., Brain glucose consumption abnormalities in neuro-Behçet's disease: a
29/6/20 © Unione europea, 2002-2020 | http://europass.cedefop.europa.eu Pagina 8 / 11
Curriculum vitae Ursini Francesco
preliminary 18F-FDG PET/CT study. Clin Exp Rheumatol, 2018. 36(6 Suppl 115): p. 148-149.
35. D'Angelo, S., et al., Safety of treatment options for spondyloarthritis: a narrative review.
Expert Opin Drug Saf, 2018. 17(5): p. 475-486.
36. Coppolino, G., et al., Exploring the effects of DPP-4 inhibitors on the kidney from the bench
to clinical trials. Pharmacol Res, 2018. 129: p. 274-294.
37. Chiaravalloti, A., et al., Ageing effect on 18F-DOPA and 123I-MIBG uptake: a cross-sectional
study. Nucl Med Commun, 2018. 39(6): p. 539-544.
38. Chiaravalloti, A., et al., Brain metabolic correlates of CSF Tau protein in a large cohort of
Alzheimer's disease patients: A CSF and FDG PET study. Brain Res, 2018. 1678: p. 116-122.
39. Castellano, A.E., et al., Prevalence of celiac disease serological markers in a cohort of Italian
rheumatological patients. Mol Imaging Biol, 2018. 11(3): p. 244-249.
40. Ursini, F., et al., Complement C3 and fatty liver disease in Rheumatoid arthritis patients: a
cross-sectional study. Eur J Clin Invest, 2017. 47(10): p. 728-735.
41. Ursini, F., et al., Old But Good: Modified-Release Prednisone in Rheumatoid Arthritis. Rev
Recent Clin Trials, 2017. 12(2): p. 124-128.
42. Ursini, F., et al., Anti-TNF-alpha agents and endothelial function in rheumatoid arthritis: a
systematic review and meta-analysis. 2017. 7(1): p. 5346.
43. Ursini, F., et al., Serum complement C3 strongly correlates with whole-body insulin sensitivity
in rheumatoid arthritis. Clin Exp Rheumatol, 2017. 35(1): p. 18-23.
44. Ursini, F., et al., Vitamin D deficiency in systemic sclerosis: a possible role of subclinical liver
fibrosis? Retrospective analysis from an Italian cohort. Clin Rheumatol, 2017. 36(12): p. 2871-2872.
45. Ursini, F., et al., International consensus: What else can we do to improve diagnosis and
therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis,
spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome
and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease
management. PLoS One, 2017. 16(9): p. 911-924.
46. Ursini, F., et al., Plantar fascia enthesopathy is highly prevalent in diabetic patients without
peripheral neuropathy and correlates with retinopathy and impaired kidney function. PLoS One, 2017.
12(3): p. e0174529.
47. Ursini, F., et al., High Prevalence of Achilles Tendon Enthesopathic Changes in Patients with
Type 2 Diabetes Without Peripheral Neuropathy. J Am Podiatr Med Assoc, 2017. 107(2): p. 99-105.
48. Ruscitti, P., et al., Biologic drugs in adult onset Still's disease: a systematic review and metaanalysis
of observational studies. Expert Rev Clin Immunol, 2017. 13(11): p. 1089-1097.
49. Ruscitti, P., et al., Prevalence of type 2 diabetes and impaired fasting glucose in patients
affected by rheumatoid arthritis: Results from a cross-sectional study. Medicine (Baltimore), 2017.
96(34): p. e7896.
50. Olivo, D., et al., Kaposi's sarcoma after T-cell costimulation blockade with abatacept in
rheumatoid arthritis: a case report. J Clin Pharm Ther, 2017. 42(3): p. 367-369.
51. De Sarro, G., et al., Poor clinical response in rheumatoid arthritis is the main risk factor for
diabetes development in the short-term: A 1-year, single-centre, longitudinal study. Sci Rep, 2017.
12(7): p. e0181203.
52. Chiaravalloti, A., et al., Functional correlates of TSH, fT3 and fT4 in Alzheimer disease: a F-
18 FDG PET/CT study. Sci Rep, 2017. 7(1): p. 6220.
53. Ursini, F., et al., Prevalence of Undiagnosed Diabetes in Rheumatoid Arthritis: an OGTT
Study. Medicine (Baltimore), 2016. 95(7): p. e2552.
54. Ursini, F., et al., Oral Metformin Ameliorates Bleomycin-Induced Skin Fibrosis. J Invest
Dermatol, 2016. 136(9): p. 1892-1894.
55. Ursini, F., et al., Complement C3 Is the Strongest Predictor of Whole-Body Insulin Sensitivity
in Psoriatic Arthritis. PLoS One, 2016. 11(9): p. e0163464.
56. Ursini, F., et al., Retrospective analysis of type 2 diabetes prevalence in a systemic sclerosis
cohort from southern Italy: Comment on "Reduced incidence of Type 1 diabetes and Type 2 diabetes
in systemic sclerosis: A nationwide cohort study" by Tseng et al., Joint Bone Spine 2016;83:307-13.
Joint Bone Spine, 2016. 83(5): p. 611-2.
57. Leporini, C., et al., Monitoring safety and use of old and new treatment options for type 2
diabetic patients: a two-year (2013-2016) analysis. Expert Opin Drug Saf, 2016. 15(sup2): p. 17-34.
58. Grembiale, R.D., et al., Correlation between elastosonography and nailfold microvascular
29/6/20 © Unione europea, 2002-2020 | http://europass.cedefop.europa.eu Pagina 9 / 11
Curriculum vitae Ursini Francesco
alterations in systemic sclerosis patients. Clin Hemorheol Microcirc, 2016. 62(1): p. 71-8.
59. Chiaravalloti, A., et al., Is cerebral glucose metabolism related to blood-brain barrier
dysfunction and intrathecal IgG synthesis in Alzheimer disease?: A 18F-FDG PET/CT study. Medicine
(Baltimore), 2016. 95(37): p. e4206.
60. Ursini, F., et al., Abatacept improves whole-body insulin sensitivity in rheumatoid arthritis: an
observational study. Medicine (Baltimore), 2015. 94(21): p. e888.
61. Ursini, F. and E. Russo, Lymphocutaneous Sporotrichosis during Treatment with Anti-TNFAlpha
Monotherapy. 2015. 2015: p. 614504.
62. Ursini, F., et al., Serum complement C3 correlates with insulin resistance in never treated
psoriatic arthritis patients. Clin Rheumatol, 2014. 33(12): p. 1759-64.
63. Patanè, M., et al., Interactions among Low Dose of Methotrexate and Drugs Used in the
Treatment of Rheumatoid Arthritis. Adv Pharmacol Sci, 2013. 2013: p. 313858.
64. Calabria, M., et al., Abatacept in psoriatic arthritis: Case report and short review. Case Rep
Rheumatol, 2013. 4(Suppl 1): p. S29-32.
65. Ursini, F., et al., Improvement in insulin resistance after short-term treatment with abatacept:
case report and short review. Clin Rheumatol, 2012. 31(9): p. 1401-2.
66. Ursini, F., S. Naty, and R.D. Grembiale, Fibromyalgia and obesity: the hidden link.
Rheumatol Int, 2011. 31(11): p. 1403-8.
67. Ursini, F., et al., Sudden progression from impaired glucose tolerance to type 2 diabetes after
discontinuation of administration of anti-tumor necrosis factor-alpha antibody infliximab. Int J
Immunopathol Pharmacol, 2010. 23(3): p. 961-3.
68. Ursini, F., et al., [The HPA axis in the pathogenesis of chronic fatigue syndrome]. Clin Ter,
2010. 161(5): p. 461-4.
69. Ursini, F., et al., Acute rhabdomyolysis during treatment with amisulpride and metformin. Eur
J Clin Pharmacol, 2010. 66(3): p. 321-2.
70. Ursini, F., G. Pipicelli, and R.D. Grembiale, Efficacy and safety of duloxetine in fibromyalgia.
Clin Ter, 2010. 161(4): p. 391-5.
71. Ursini, F., et al., Kaposi's sarcoma in a psoriatic arthritis patient treated with infliximab. Int
Immunopharmacol, 2010. 10(7): p. 827-8.
72. Ursini, F., S. Naty, and R.D. Grembiale, Infliximab and insulin resistance. Autoimmun Rev,
2010. 9(8): p. 536-9.
73. Ursini, F., et al., CD4+ T-cells lymphocytosis and reduction of neutrophils during treatment
with adalimumab: Challenge and dechallenge study. Clin Immunol, 2010. 135(3): p. 499-500.
74. Ursini, F., [TNF-alpha and insulin-resistance: metabolic effects of in vivo therapeutic
blockade]. Reumatismo, 2009. 61(4): p. 254-9.
75. Lakshmikanth, T., et al., NCRs and DNAM-1 mediate NK cell recognition and lysis of human
and mouse melanoma cell lines in vitro and in vivo. J Clin Invest, 2009. 119(5): p. 1251-63.